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Abstract
Diabetic retinopathy and diabetic foot ulcer are the most frequent, but also 
the most disabling complications of diabetes mellitus, with a sinister impact on 
patients’ quality of life. Microvascular changes related to the deleterious effect of 
chronic hyperglycemia play an important role in the pathophysiology of both clini-
cal entities by multiple molecular pathways. Vision-threating diabetic retinopathy 
may be treated by laser photocoagulation, anti-vascular endothelial growth factor 
(VEGF) agents and vitreoretinal surgery. Diabetic foot lesions are best treated by 
revascularization if needed, off-loading, infection control and therapeutic adjuncts 
(e.g. special dressings). Treatment should ideally be offered by a multidisciplinary 
expert team. Prevention and early detection, along with adequate control of 
glucose, lipids and arterial hypertension are of paramount importance to avoid and 
mitigate these fearful complications.
Keywords: microvascular complications, diabetic retinopathy, risk factors, 
ophthalmoscopy, angiography, laser photocoagulation, diabetic foot,  
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1. Introduction
In diabetes (DM), chronic complications related to the direct or indirect effects 
of prolonged hyperglycemia on the vasculature have been classified into macrovas-
cular and microvascular complications, depending on the size of affected vessels 
and the pathophysiological mechanisms involved. Microvascular disease includes 
retinopathy, nephropathy and neuropathy.
Diabetic retinopathy, one of the first manifestations of microvascular disease, 
remains today, despite improvements in monitoring and treatment, one of the 
leading causes of blindness worldwide. Epidemiological studies estimate that 
approximately 40% of subjects with DM type I over 40 years of age have retinal 
microvascular changes, of which 8.2% exhibit impaired visual acuity [1, 2]. Both 
DM types are associated with impaired retinal microcirculation. After 20 years 
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from the onset of DM, almost all patients with type 1 DM (T1DM) and over 60% of 
those with type 2 DM (T2DM) will be affected [3]. Furthermore, decreased vision 
as a result of diabetic retinopathy has a negative impact on the quality of life of 
patients and their ability to successfully manage DM [4].
Diabetic foot results from diabetic neuropathy and/or peripheral arterial disease 
and affects annually between 9.1 to 26.1 million [5]. It is a chronic disabling and 
progressive complication, with potential deformities, chronic ulcerations and infec-
tions. Diabetic foot ulcers (DFUs) are encountered in 15% of DM patients, of whom 
15-20% reach amputations. The latter lead to increased morbidity and decreased 
quality of life, but also an important burden on national healthcare systems, with 
increased health costs and hospitalization [6, 7].
2. Diabetic retinopathy
2.1 Risk factors
2.1.1 DM duration and poor glycemic control
Diabetic retinopathy (DR) is a chronic complication associated with long DM 
duration and poor glycemic control, the overall incidence of DR and of vision-
threatening forms of DR (VTDR) being higher in T1DM than in T2DM [8].  
The United Kingdom Prospective Diabetes Study (UKPDS) showed that both the 
incidence and progression of DR correlate with elevated HbA1c, emphasizing the 
importance of good glycemic control to prevent visual impairment [9]. Every 1% 
decrease in HbA1c leads to a 40% reduction in the risk of developing retinopathy, a 
25% reduction in the risk of progression to vision-threatening retinopathy, and a 
15% reduction in the risk of blindness [10].
2.1.2 Arterial hypertension
The correlations between cardiovascular risk factors and the occurrence and 
evolution of DR are still a subject of study. However, there is clear evidence that the 
processes of arteriolosclerosis and the mechanical trauma to the vascular endothe-
lium caused by elevated systolic and diastolic blood pressure are both cofactors in 
worsening DR. Some but not all studies have shown a negative impact of high blood 
pressure on DR [9, 11, 12]. The UKPDS has demonstrated a significant correlation 
between systolic arterial hypertension and DR incidence in T2DM. Thus, patients 
with blood pressure (BP) > 140 mmHg have a 2.8 times higher risk of developing 
DR than those with BP <125 mmHg. In the study of Lurbe et al. [13], in a cumulative 
exposure model, HbA1c and elevated diastolic BP values  are predictive factors for 
the occurrence and progression of RD. In the Wisconsin Epidemiologic Study of 
Diabetic Retinopathy (WESDR), diastolic BP emerged as a significant risk factor for 
DR progression in T1DM, but no correlations were found for systolic BP or T2DM 
[14, 15]. Therapeutic lowering BP was found to have a protective role on retinal 
lesions in several studies supporting the recommendations for tight blood pressure 
control to further prevent visual loss n T2DM [9, 14, 16].
2.1.3 Lipidic disorders and serum LDL
Unlike glycemic control, the role of serum lipids in DR pathogenesis is less clear. 
There is no parameter in the lipid profile that is strictly associated with the incidence 
or progression of DR. However, elevated total cholesterol, LDL-cholesterol, Apo B 
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and Apo B/Apo A ratio are correlated with the appearance of hard exudates, these 
being lipoprotein extravasations in the retinal capillaries. Hadjadj et al. showed that 
serum triglyceride levels are correlated with the occurrence of nephropathy and 
retinopathy in patients with T1DM [17]. Several randomized trials confirmed that 
the treatment of dyslipidemia can prevent the development of DR [14, 15, 18–21].
2.1.4 Genetic predisposition
Several studies have revealed that in young adults with T1DM, genetic predisposi-
tion for the development of DR is connected with the presence of HLA DR3/DR4 
antigens. Furthermore, different alleles for codification of cytokines and chemokines, 
as well as vascular endothelial growth factor (VEGF) and transforming growth factor 
(TGF)beta1 were characterized, explaining different predisposition for DR in diabetic 
patients. VEGF plays a key role in increased microvascular permeability and neovascu-
larization in proliferative diabetic retinopathy. The VEGF gene is located on chromo-
some 6 (6p21.3) and is highly polymorphic in the promoter region, correlated with 
VEGF expression and activity. In a study by Buranczynska et al., the presence of the 
D allele at −2549 in the promoter region of the VEGF gene enhanced gene expression 
[22]. The DD genotype was associated with DR but not with nephropathy, suggesting 
a cell-specific target of the VEGF isoform. In a study of Jalal and Kalia, regarding the 
polymorphism of VEGF genes in India, allele A and AA genotype of rs2146323 were 
significantly correlated both with incidence and with severity of DR [23]. Awata et al. 
described C (−634) G polymorphism of VEGF gene to be related to macular edema 
as well as diabetic retinopathy [24]. Ray et al. identified VEGF −460 C genotype 
to increase VEGF basal promoter activity by 71%, leading to a 2.5 increased risk of 
proliferative DR [25]. TGF beta signaling is considered to have an immunosuppressive 
role in the retina. Disorders affecting this pathway lead, at least in experimental animal 
models, to loss of pericytes, microaneurysms and leakage, finding resembling diabetic 
retinopathy [26]. Beránek et al. found a more frequent incidence of 915G/C (R25P) 
polymorphism of TGF beta gene in patients with DR compared to control subjects [27].
2.1.5 Pregnancy
Hormonal alterations during pregnancy were found to be an independent risk 
factor both for onset and for progression of DR, especially PDR, posing many chal-
lenges regarding the management of these patients [28–30]. Another mechanism is 
pregnancy-induced hypertension and pre-eclampsia [31].
2.1.6 Ocular and systemic inflammation
Recent studies focus on the significance of inflammation in the developments 
of DR [32–36]. There is strong evidence that ischemia and retinal hypoxia induce 
release of VEGF and inflammatory molecules at the level of endothelial and glial 
cells. Furthermore, several studies support the idea that ocular inflammatory disor-
ders, such as prolonged post cataract surgery healing, uveitis, keratitis, are related 
to DR progression [32–36].
There are increased evidences that chronic systemic inflammation is also 
related to increased risk of DR onset and progression. In an experimental animal 
model, recurrent exposure to systemic LPS leads to injury of capillary endothe-
lium and in vivo thinning of the retina in hyperglycemic mice, but not in healthy 
controls [37]. There are clinical evidences of increased incidence of DR and PDR in 
long standing non-healing foot ulcer, that could be explained due to the associated 
chronic low-grade systemic inflammation [38–42].
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2.1.7 Antidiabetic treatment and macular edema
The correlations between antidiabetic mellitus medication and the risk of 
macular edema is still a subject of research. In a comprehensive systematic review 
and meta-analyses, Zhu and col. found that insulin use, as well as thiazolinedione 
(TZD) and meglitinide might increase the risk of macular edema, metformin has 
no statistically significant effect, while the use of sulfonylureas seems to have 
a protective role [43]. The physiopathological mechanisms are not completely 
understood, but experimental studies indicate that insulin and TZD may induce 
changes in retinal flow and increased expression of VEGF and breakdown of 
retinal-vascular barrier [43–46].
2.2 Pathophysiology
The pathological changes that lead to diabetic retinopathy are attributable to 3 
main factors:
• small vessel wall damage:
• changes in blood flow
• alterations in platelet function
2.2.1 Lesions in small vessel wall
Microvascular changes in the retinal capillaries are due to chronic hyperglycemia 
by different mechanisms, such as:
2.2.1.1 Aldose-reductase and intracellular polyol pathway
Aldose reductase is an enzyme that converts glucose to sorbitol, which 
induces osmotic stress by intracellular accumulation. In animal models, this 
phenomenon leads to microaneurysmal dilatations of the vascular wall, basal 
membrane thickening and loss of the pericytes [47]. However, experimental 
studies of treatment with aldose reductase inhibitors have not obtained satisfac-
tory clinical results.
2.2.1.2 Advanced glycosylated end products (AGEs)
Chronic hyperglycemia leads to non-enzymatic glycation or glycoxidation of 
proteins, resulting in accumulation of AGEs. This process affects both intra- and 
extracellular proteins, resulting in functional impairment. Deposits of AGEs in 
the extracellular matrix and subendothelial space lead to permanent alterations of 
intercellular junctions, monocyte migration and activation of nuclear factor (NF)-
κB along with activation of pro-inflammatory pathways [48, 49]. In experimental 
models, increased AGEs accumulation is associated with loss of pericytes and 
microaneurysm formation in retinal capillaries [50].
2.2.1.3 Oxidative stress and ROS
Hyperglycemia induces mitochondrial dysfunction and endoplasmic reticulum 
stress, with increased production of free radicals and reactive oxygen species (ROS) 
accumulation [49]. These degrade lipids, proteins and ribonucleic acid (RNA) chains. 
5
Microvascular Complications of Diabetes Mellitus: Focus on Diabetic Retinopathy (DR)…
DOI: http://dx.doi.org/10.5772/intechopen.96548
Furthermore, experimental studies have proved a “hyperglycemic memory”: in 
subjects with long periods of poor glycemic control, reversal of hyperglycemia fails to 
normalize increased oxidative activity in the retina [51]. Treatment with antioxidants 
and vitamin E alleviates endothelial dysfunction, but does not prevent the onset and 
progression of DR and other microvascular complications. Isolated experimental 
blockade of each of these pathways does not stop retinal microvascular damage, 
suggesting that the effects of hyperglycemia are manifested at the cellular and 
extracellular levels. Recently, experimental and clinical studies have demonstrated 
that inflammation biomarkers and pathways play a significant role in the aggrava-
tion of lesions and the evolution towards retinal neovascularization. A large array of 
cytokines and chemokines were found in increased concentrations in patients with 
DM, both in ocular samples and in serum: interleukin (Il)1beta, Il 2, 4, 6, 8, TNFalfa 
and (monocyte chemoattractant protein) MCP-1 [38, 42, 52–54]. Recent works have 
revealed that the TXNIP/NLRP3 Inflammasome activation pathways may contribute 
to pathologic neovascularization encountered in advanced stages of PDR [50, 54, 55].
2.2.1.4 Nitric oxide (NO) deficiency
Hyperglycemia induces decreased synthesis and increased consumption of NO 
by multiple pathways: activation of protein kinase C (PKC) in endothelial cells, 
oxidation of the reduced form of nicotinamide adenine dinucleotide phosphate 
(NADPH) via aldose reductase pathway, and non-enzymatic production of super-
oxide by AGEs. NO plays key roles in microcirculation, by regulation of arteriolar 
tone, platelet stabilization and preventing leukocyte adherence at the vascular wall. 
Decreased local levels of NO promotes vasoconstriction, microvascular occlusions 
and secondary retinal ischemia.
2.2.2 Changes in blood flow and platelet function
General changes in blood favor small vessel obstructions with secondary retinal 
ischemia:
• increased hematocrit and blood viscosity related to high liver synthesis of 
fibrinogen and alfa2 globulins
• more rigid erythrocytes, with increased tendency to thrombosis
• increased platelet adhesion and aggregation
• activation of peripheral leukocytes, increased adherence to endothelial cells via 
beta-2 integrin expression and synthesis of mediators of inflammation
2.2.2.1  Pigmented Epitelium Derived Factor (PEDF) decrease and retinal 
neurodegeneration
PEDF is a trophic factor expressed by a multitude of retinal cells, an antago-
nist of VEGF. It decreases vascular permeability and plays an antioxidant role, 
protecting retinal cells from ROS. In the experimental setting, PEDF is decreased 
in aqueous and vitreous humor, early in preclinical stages of DR. The pathogenic 
mechanisms are supposed to be related with decreased insulin, as well as increased 
toxic mediators, such as glutamate. These early changes may induce mild changes 




All these molecular mechanisms may lead to:
• alteration of tight junctions in endothelial cells, compromising the blood-
retinal barrier, increasing extravasation of fluid in the retinal space and the 
formation of lipoprotein exudates and retinal edema
• loss of pericytes, with the appearance of focal vascular dilations and 
microaneurysms
• thickening, hyalinization of the basement membranes, with loss of elastic-
ity of the vascular wall and autoregulatory capacity. This, together with the 
alterations of blood flow and platelets, favors microvascular occlusions, with 
the appearance of ischemic, hypoxic retinal areas.
The first areas affected by thrombosis and ischemia are in the middle retinal 
periphery, and the answer is to release a range of mediators, of which the key role 
is played by VEGF, which promotes retinal neovascularization and interruption of 
blood flow in many areas (optical disc, macula, iridocorneal angle and iris). The 
response to retinal hypoperfusion, a maladaptive protective mechanism, leads 
to the appearance of fragile new vessels, prone to repeated bleeding and leakage, 
ultimately destroying normal retinal architecture (Figure 1).
2.3 Clinical manifestations of DR
Fundus examination documents the presence and severity of retinal lesions. 
Clinical signs include:
Figure 1. 
Pathogenesis of diabetic retinopathy.
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• Microaneurysms: tiny round red dots, typically located initially temporal 
to the fovea; sometimes hard to be differentiated from dot hemorrhages in 
ophthalmoscopy; they are best shown by fluorescein angiography
• Retinal hemorrhages: a) “dot-blot” hemorrhages result from the venous end 
of the capillaries and are located in the middle layer of the retina; b) “flame-
shaped” hemorrhages arise from pre-capillary arterioles and are located more 
superficially in the retinal nerve fiber layer
• Retinal edema: elevated, white-greyish appearance of the involved area; may 
be a consequence of leakage and fluid accumulation or of retinal ischemia 
(intracellular retinal edema). When foveal region is involved, it may assume a 
cystoid appearance and fluorescein angiography reveal a flower-petal pattern
• Hard exudates: these are well delineated, small, bright yellowish retinal 
lesions, formed by extravasated lipoproteins and lipid-filled macrophages 
and are mainly located in the outer plexiform layer. They are considered a sign 
of current or previous macular edema. When located in the macular region, 
they tend to organize in a circinate manner. They could resorb spontane-
ously months after the leakage is stopped, otherwise, chronic leakage leads to 
enlargement of the exudates and cholesterol accumulation.
• “Cotton wool” spots: these are small, whitish, fluffy superficial lesions, that 
cover the underlying retinal vessels and bear the significance of focal retinal 
ischemia and infarction. They are composed by neuronal debris and can disap-
pear in time by autolysis and phagocytosis.
• Venous loops and venous beading (VB): these frequently occur adjacent to 
areas of nonperfusion and bear the significance of increasing retinal ischemia
• Intraretinal microvascular abnormalities (IRMA): these are arteriolo-
venous shunts, bypassing the capillary bed, and are considered an indicator of 
capillary occlusion and retinal ischemia. Together with VB, they are considered 
the most significant predictor of progression to PDR [58].
• Neovessels: these are thin, with a single cell layer wall, extremely fragile, with a 
lace-like appearance and may be situated at the surface of the optic disk or else-
where, in general at the periphery of the areas of non-perfusion. They can be best 
evidenced by fluorescein angiography and optical coherence tomography (OCT).
2.4 Staging of DR
Dr is classically referred as: non-proliferative (NPDR) and proliferative (PDR). 
The classification is determined by the presence of retinal neovascularization. 
Recent Guidelines of International Council of Ophthalmology for Diabetic Eye 
Care recommends the following staging system, based on findings encountered in 
ophthalmoscopy, to be used in clinical practice (Table 1).
The ICO guidelines also refer to the location, extension of the diabetic macu-
lar edema (DME), as it is an important cause of decreased vision in DR, even in 
the absence of neovessels. Central involved DME is considered to be an area  
of retinal thickening in the macula that does involve the central subfield zone  
(of 1 mm in diameter).
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2.5 Clinical forms of DR associated with high risk of vision loss
Diabetic maculopathy is the most frequent cause of decreased vision encoun-
tered in patients with T2DM. It can be manifest in every stage of the DR and 
represents the involvement of the fovea by hard exudates, macular edema due to 
fluid extravasation or by macular ischemia. In early stages, the loss of vision is mild; 
however, if untreated, it can may to permanent photoreceptor damage.
DME is considered clinically significant if [61–63]:
• located at or within 500 μm of the center of the macula
• hard exudates at or within 500 μm of the center if associated with thickening 
of adjacent retina
• the area of retinal thickening is larger than one optic disc area and is located 
within 1 disc diameter of the center of macula
2.5.1 Advanced diabetic ocular disease
Advanced diabetic disease can remain asymptomatic for a long period of time, 
due to slow proliferation of the retinal neovessels and their location, usually in 
mid-periphery. It consists of retinal neovessels that grow into elevated fibrovascular 
membranes that enter the vitreous body, leading to serious complications: vitreous 
hemorrhage and retinal detachment [62]. Proliferation of the abnormal vessels 
at the level of iris and iridocorneal angle led to neovascular glaucoma, with poor 
clinical outcomes. Ophthalmological periodical screening is extremely important in 
early identifying and referral to laser therapy. In advanced stages, serious complica-
tions appear and the vision loss is irreversible.
Diabetic maculopathy is the most frequent cause of decreased vision encountered 
in patients with T2DM.
DR Findings on Dilated Ophthalmoscopy
No apparent DR No abnormalities
Mild NPDR* Microaneurysms only
Moderate NPDR Microaneurysms + other signs:
• dot and blot hemorrhages
• hard exudates
cotton wool spots
Severe NPDR Moderate NPDR with any of the following:
• Intraretinal hemorrhages ≥20 in each quadrant;
• Definite venous beading (VB) in 2 quadrants;
• Intraretinal microvascular abnormalities (IRMA) in 1 quadrant;
and no signs of proliferative retinopathy
PDR* Severe non-proliferative DR + one of the followings:
Neovascularization
Vitreous/preretinal hemorrhage
*NPDR: non proliferative diabetic retinopathy; *PDR: proliferative diabetic retinopathy
Table 1. 
International Classification of Diabetic Retinopathy [57].
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2.6 Diagnosis of DR
Early detection of DR depends on educating DM subjects, as well as their 
families, friends, and health care providers about the importance of regular eye 
examination. This holds true for asymptomatic subjects as well.
Initial ophthalmological examination in a patient with suspected/confirmed DR 
should include the following:
• Visual acuity
• Measurement of intraocular pressure (IOP), due to the possible risk of developing 
neovascular glaucoma
• Slit-lamp exam +/- gonioscopy if iris neovascularization is observed or IOP is 
elevated
• Fundus examination with dilated pupil
A variety of imaging techniques are useful to detect, classify and monitor DR, as 
well as efficacy of treatment: fundus photography, fluorescein angiography, optic 
coherence tomography (OCT) and OCT angiography.
2.6.1 Ophthalmoscopy and Fundus Photography
Currently, the two most sensitive methods are retinal photography and slit-lamp 
examination through dilated pupils. Direct ophthalmoscopy by ophthalmologists 
or trained technicians yields 80% sensitivity and >90% specificity [64]. It is cheap 
and is considered the method of choice. Fundus photography has the advantage 
of creating a permanent record, and for that reason, it is the preferred method for 
retinopathy assessment (Figures 2–4).
Figure 2. 
“Background” diabetic retinopathy: few dot hemorrhages (blue arrows) (Dr. Ana Dascalu’s private collection, 




Incipient PDR: large ischemic area situated temporally to the macular region, with hard exudates, dots 
hemorrhages, venous loops, IRMA and intraretinal neovessels; in the mid periphery, pigmented lesions post 
laser photocoagulation (Dr Ana Dascalu’s private collection, Emergency University Hospital Bucharest, 
Ophthalmology Department).
2.6.2 Fluorescein angiography
Fluorescein angiography is an invasive, costly, and time-consuming technique 
but is a sensitive method to detect vascular changes due to rupture of the inner and 
outer blood retinal barrier in the course of DR [63, 65, 66]. The retinal vasculature 
is visualized with great accuracy: the examiner may identify tiny microaneurysms 
and differentiate between microaneurysms (hyperfluorescent) and puncti-
form hemorrhage (hypofluorescence by masking effect). It is an indispensable 
Figure 3. 
Retinophotography: Severe NPRD: multiple dot and blot hemorrhages, hard exudates, cotton wool spots 
(blue arrows), macular edema, VB (green arrow) and IRMA (black arrows) (Dr. Daniela Stana’s private 
collection, Emergency University Hospital Bucharest, Ophthalmology Department, PhD thesis).
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exploration before planning different laser treatment, for example to distinguish 
retinal edema by leakage (which appears white due to dye accumulation) from 
ischemic retinal edema (which appears as hypofluorescent). In the latter case, the 
application of laser impacts is not recommended because it leads to exacerbation of 
retinal ischemia (Figure 5).
2.6.3 Optical coherence tomography (OCT) and OCT-angiography (OCT-A)
OCT is a completely non-invasive, reproducible and quantifiable. It provides 
high-resolution images of the retinal layers, choroid, vitreous gel, and the vitreo-
retinal interface and has become the gold standard for diagnosis, assessment of 
treatment response, and follow-up up of patients with diabetic macular edema.
OCT angiography (OCTA) is a new non-invasive imaging technique that 
employs motion contrast imaging to high-resolution volumetric blood flow infor-
mation, rapidly generating images similar to angiographic images [63, 65–67]. It 
provides a highly detailed view of the retinal vasculature, which allows for accurate 
delineation of the foveal avascular zone (FAZ) and detection of subtle microvas-
cular abnormalities, including FAZ enlargement, areas of capillary non-perfusion, 
and intraretinal cystic spaces [66]. The possibility of detecting microvascular 
changes in diabetic eyes before the presence of visible microaneurysms may have 
important implications in the future. In this sense, OCTA could be able to quickly 
identify subjects at risk of DM (Figures 6 and 7).
2.7 Treatment
2.7.1 Primary prevention
Follow-up of patients with DR involves the ophthalmologist and the diabetolo-
gist. Extensive studies in large groups of diabetic patients have shown the beneficial 
role of strict control of blood glucose, hypertension and dyslipidemia in both 
Figure 5. 
Fluorescein Angiography: Severe NPRD: numerous microaneurysms (hyperfluorescent dots), areas of non-
perfusion (hypofluorescent, blue arrows), venous loops and IRMA, with diffuse leakage (hyperfluorescent, 





Optical coherence tomography (OCT) macular change analysis (before and 1 month after intravitreal anti = 
VEGF): hard exudates intraretinal edema with disorganization of the normal foveal architecture; macular and 
paramacular temporal edema decreases in area and height (Dr. Ana Dascalu’s private collection, Emergency 
University Hospital Bucharest, Ophthalmology Department).
Figure 7. 
OCT-A: (a) enlargement of FAZ and perifoveolar area of microvascular abnormalities; (b) mild FAZ 
enlargement, multiple microaneurysms (Dr. Daniela Stana’s private collection, PhD Thesis, Emergency 
University Hospital Bucharest, Ophthalmological Department).
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preventing and slowing the progression of DR. DCCT and UKPDS showed the 
importance of a good glycemic control in preventing microvascular damage in 
diabetes [68, 69]. Furthermore, every decrease with 10 mm Hg of systolic blood 
pressure is associated with a reduction of 35% in the risk of DR progression and of 
50% in the risk of blindness [69]. Maintaining HbA1c below 7.0% (53 mmol/mol) 
and a systolic blood pressure below 140 mmHg is considered a realistic therapeutic 
target in clinical practice. Currently, the recommended serum lipid levels in DM are 
an optimal LDL cholesterol concentration of <100 mg/dl and desirable triglycerides 
levels of <150 mg/dl [69–72].
2.7.2 Retinopathy screening
DR remains clinically silent, a long period of time until damages become 
irreversible. Ophthalmologic monitoring of DM subjects is essential. Frequency 
of screening depends on the severity of DR and the co-existence of risk factors. 
The follow-up schedule recommended by the ICO (International Council of 
Ophthalmology) Guidelines for Diabetic Eye Care is presented in Table 2 [61].
2.7.3 Laser photocoagulation
2.7.3.1 Classical laser
Laser therapy has been used in DR for over 60 years and remains the mainstay of 
treating the ischemic retina. Applied early in severe NPDR and PDR, laser therapy 
leads to the prevention/regression of neovascularization and to the remission of 
retinal edema. Clinical studies confirm the effectiveness of laser photocoagulation 
by reducing vision loss by approximately 50% in patients with PDR. It is based on 
application of 1000-2000 laser shots, lasting 100 milliseconds, 200-250 mW of 
power with a size of 200-500 micrometers at the level of the middle and extreme 
periphery of the retina, spaced at a distance by a spot diameter, in order to destroy 
DR staging Follow-up Schedule for 
ophthalmologists
Therapy
No apparent DR 1-2 years Observation
Mild NPDR 6-12 months Observation
Moderate NPDR 3-6 month Observation
Severe NPDR <3 months; Pan-retinal photocoagulation should be 
considered
Proliferative DR <1 month; Pan-retinal photocoagulation
Stable (Treated) PDR 6-12 months Observation
Diabetic Macular 
Edema severity








1-3 month; Focal laser photocoagulation/ anti- 
VEGF therapy should be considered
Stable DME 3-6 month Observation
Table 2. 
ICO Guidelines for Diabetic Eye Care: screening and follow-up schedule for diabetic retinopathy.
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the VEGF-secreting ischemic retina. Immediate complications are related to eye 
discomfort (tingling sensation/low-intensity pain) and mild ocular inflammation 
(caused by retinal burns). For this reason, it is recommended to space the laser 
photocoagulation in 3-4 sessions. In the long run, potential complications include 
hemeralopia, "fan shaped" visual field changes, or even concentric narrowing of the 
visual field through widening of scars and subretinal fibrosis. Other less frequent 
side effects are membrane injury, with secondary choroidal neovascularization, 
damage of ciliary nerves with permanently mydriasis and loss of accommodation, 
uveal effusion, angle closure glaucoma, serous retinal detachment, and vitreous 
hemorrhage [73–75].
2.7.3.2 Multispot laser
This technique allows the delivery of laser shots in a much shorter time and in a 
semi-automatic manner. These are much finer and at a lower intensity, threshold or 
subthreshold, causing lesser heat and consequently inflammation in the pigmented 
retinal epithelium. Clinical studies have shown that the effectiveness of the method 
is similar to classical laser, but fewer complications are encountered regarding 
retinal scarring and the impact on the visual field.
2.7.3.3 Laser photocoagulation in diabetic macular edema (DME)
In the case of exudative non-central DME, laser treatment may be considered 
as an alternative or in combination with intravitreal injections with anti-VEGF. In 
this case, the laser spots are finer, with a size of 50-100 μm, and lower energy. Laser 
treatment is inefficient in the case of ischemic macular edema, and so fluoran-
giography is necessary before therapeutic planning. In the early treatment diabetic 
retinopathy study (ETDRS) study, when comparing laser photocoagulation with no 
treatment, there was a decrease in DME from 24% to 12% after 3 years follow-up, 
while visual acuity improved in only 3% of patients [76].
2.7.4 Intravitreal anti-VEGF
Clinical and experimental studies have revealed increased VEGF concentra-
tion in ocular samples early in the evolution of DR, documenting its role both in 
increased vascular permeability and in vascular proliferation. Hence, anti-VEGF 
agents were used first in the treatment of DME and later in PDR management 
[77] (Table 3).
Clinical studies showed that Pegaptanib is the least effective in preventing 
neovascularization. Comparative studies between bevacizumab, ranibizumab and 
aflibercept found that they are all effective to decrease DME. However, aflibercept 
is most powerful in subjects with worse visual acuity [77, 78]. Still, the effect of 
intravitreal anti- VEGF is temporary and intravitreal therapy should be repeated 
according to clinical outcome.
2.7.5 Intravitreal steroids
In cases of DME resistant to anti-VEGF therapy after 3 monthly injections, 
intravitreal triamcinolone injection or fluocinolone are a therapeutic alternative to 
reduce DME and improve vision [79]. Their main untoward effects are cataract and 
transient increase of intraocular pressure.
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2.7.6 Surgical management of DR
Vitreoretinal surgery is crucial in managing advanced DR, in order to mitigate 
visual loss. Its main indications include vitreous hemorrhage interfering with 
photocoagulation, tractional and combined tractional and rhegmatogenous retinal 
detachment, dense premacular hemorrhage and DME with with vitreo-macular 
traction [80]. The objectives of surgical removal of the vitreous (vitrectomy) 
include removal of vitreous opacity (usually blood) and/or fibrovascular prolif-
eration, relieving retinal traction, achieving retinal reattachment, and allowing 
completion of scatter laser photocoagulation. A large case series showed that sight 
threatening complications are rare and in approximately 90% of cases, vision is 
improved or stabilized [81]. Vitrectomy may also be beneficial for maculopathy 
when traction from the vitreous gel contributes to fluid accumulation.
3. Diabetic foot ulcers (DFUs)
3.1 Risk factors
The main risk factors of DFUs include DM duration and high HbA1c [82–88]. 
The EURO-Diab group has identified hypertension, smoking and lipid disorders 
(hypertriglyceridemia, hypercholesterolemia) as additional risk factors [82, 83]. In 
Western countries, the male sex appears to be more commonly affected, with a risk 
ratio of 1.6. The co-existence of other microvascular complications (DR, nephropa-
thy) increases the risk of DFUs.
Precipitating trauma is important. However, history of trauma is only identified 
in 48% of patients with DFUs. By contrast, foot injury without an apparent cause 
usually results from repeated minor injuries by inappropriate footwear [88–90]. 
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Amin and Doupis have estimated that 45-60% of DFUs are mainly due to neuropa-
thy, while 45% of DFUs are due to both diabetic neuropathy and peripheral arterial 
disease [87]. Like DR, diabetic neuropathy is also a very frequent DM complication 
and its prevalence increases with DM duration [90]. The other important driver of 
DFUs is ischemia from peripheral arterial disease (PAD). Visual impairment, foot 
deformities and past history of DFU also increase the risk of DFUs [85, 86].
3.2 Pathophysiology
The underlying mechanisms of DFUs include diabetic neuropathy, PAD and 
infection.
Diabetic neuropathy may affect the motor, sensory and autonomic nerves. 
Thickening of the basement membranes, endothelial hyperplasia in the vasa 
nervorum lead to thinning of the vascular lumen and secondary ischemia [90, 91]. 
On the other hand, metabolic disorders caused by chronic hyperglycemia, with the 
formation of AGEs, polyol pathways, increased oxidative stress levels and enzy-
matic activation of PKC also have direct toxic effects on nerve fibers.
Autonomic neuropathy causes arteriolo-venular shunts with secondary 
decreased blood flow in capillaries, but also anhidrosis, resulting in dry skin, thin, 
prone to cracking and ulceration. Sensory neuropathy leads to sensory (inability 
to feel warm/cold, pain, pressure), rendering the foot prone to undetected acute 
or chronic traumas [90, 91]. Motor neuropathy leads to imbalance between plantar 
flexors and extensors, with characteristic deformities, such as hammer toe, claw toe 
etc, and leading to high planter pressures in some small foot areas [92–94].
PAD leads to lower-extremity ischemia. In diabetes, it is usually located in the 
infra-popliteal arteries, less so at the iliofemoral level [89, 95]. Ischemia portends 
even more ominous outcomes [91, 96].
Pesently, micro and macrocirculatory disorders are considered not as separate 
entities, but more as a continuum in DM [97], neovascularization of vasa vasorum, 
with secondary hemorrhages and platelet aggregation facilitating the progression of 
atherosclerosis and intraluminal obstruction.
DFUs are frequently infected. The most common germs involved are staphy-
lococci and streptococci, but deep infections are usually polymicrobial including 
gram positive, gram negative and even anaerobic germs [98, 99]. Chronic hypergly-
cemia and chronic hypoxia predispose to severe infections [99].
3.2.1 Clinical signs-staging systems
DFU represents any full-thickness ulcer below the ankle in DM. The initial signs 
and symptoms depend on the pathophysiological mechanism involved (neuropathy 
and/or PAD). Subjects with diabetic neuropathy are usually initially asymptomatic, but 
a minority of them may later develop neuropathic symptoms (numbness, paresthesia, 
lancinating or burning pain) with nocturnal exacerbation. In the event of PAD, inter-
mittent claudication or even ischemic rest pain and gangrene may develop (Figure 8).
Usually, DFUs develop in an area exposed to increased pressure, with a non-
healing tendency, often neglected in early stages due to diminished pain sensation. 
In the vent of infection, signs of local inflammation may be added (redness, swell-
ing, pain, pus secretion etc).
Several staging systems were developed in order to characterize the pathogenic 
pathway and the severity and extension of ulcer. The International Working Group 
on the Diabetic Foot Risk Classification System (IWGDF) refers mainly at the sever-
ity of neuropathy and coexistence or not of the peripheral ischemia [100], while the 
Wagner classification describes the extension and depth [101] (Tables 4 and 5).
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Patient history is necessary to provide information on DM duration, glycemic 
control, associated risk factors and any prior lesions/amputations.
Clinical examination should look for skin disorders, foot deformities, nail 
lesions, blisters etc. also be documented. It must also include an evaluation of 
neuropathic deficits, PAD and infection. Signs of limb threatening infection include 
bullae, ecchymoses, soft tissue crepitus and rapid spread of infection [102, 103].
Evaluation of sensory neuropathy is very important to establish whether the patient 
has lost the protective sensation, making him prone to accidental trauma. Hot/cold 
discrimination, pain perception, light touch and vibration perception, as well as 
protective sensation must be tested [95–99]. The latter is best assessed by the 10 g 
Semmes Weinstein monofilament or the measurement of the vibration perception 
Figure 8. 
Distal toe gangrene and extensive infection and inflammation at the level of the forefoot and mid foot  
(Dr. Dragos Serban’s private collection).
Grade 0 Intact sensation
Grade 1 Diminished sensation
Grade 2 Diminished sensation+ foot deformities (hammertoes, claw toes) +/-peripheral 
arterial disease
Grade 3 Previous/present ulcer or amputation
Table 4. 
IWGDF risk classification [96].
Grade 0 No ulcer in high-risk patients
Grade 1 Superficial ulcer
Grade 2 Ulceration involving tendons, ligaments, muscles, joints, not exposed to bone, without 
cellulitis or abscess
Grade 3 Deeper ulcers, with frequent bone complications of osteomyelitis, abscesses or 
cellulitis.
Grade 4 Forefoot gangrene.
Grade 5 Gangrene extended to midfoot/hindfoot
Table 5. 
Wagner Classification of DFU [101].
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threshold (VPT) with a neurothesiometer [93–95, 102, 103]. Tendon reflexes and 
muscular strength are also a part of the examination [95–99]. Finally, sudomotor 
dysfunction (reduced sweat production) is best examined by the Neuropad indicator 
test, which is based on a colour change from blue to pink [96, 97]. Indeed, this test 
has recently been identified as an independent risk factor of DFUs at 5 years [104].
3.3.1.1 Peripheral neuropathy screening
Evaluation of bilateral sensorial neuropathy in clinical practice requires neuro-
logical trained specialist and electrophysiological tests, which an increased burden 
on the national healthcare systems. In order to better select the patients who are 
more probably affected by neuropathy, a simpler tool was developed in 1994, 
namely Michigan Neuropathy Screening Instrument (MNSI) [105, 106]. It com-
prises a 2-step evaluation: first, a 15-item self-administered questionnaire that is 
scored by summing abnormal responses, followed by lower extremity examination 
(deformities, non-healing ulcers), assessment of ankle reflexes and of vibratory 
sensation. According to Herman and col., a score of more than 4 should raise the 
suspicion of peripheral sensorial neuropathy [106].
3.3.1.2 Peripheral arterial disease
Documenting the presence and the severity of ischemia is extremely important. 
Examination includes: a) palpation of peripheral pulses at the dorsalis pedis and 
the posterior tibial arteries; b) measurement of the ankle-brachial index (ABI) by a 
Doppler device [99, 100]. ABI evaluates the ratio of systolic arterial pressure at the 
brachial over the ankle level [107, 108]. Normal values range between 0.9-1.3, while 
values exceeding 1.3 point to calcified, uncompressible arteries, in which case the 
test cannot be used [99]. Similarly, one may measure the toe-brachial index (TBI), 
given that small digital arteries are rarely calcified: TBI<0.7 confirms the diagnosis 
of PAD [108]. More sophisticated evaluation (ultrasound, angiography) are used 
when necessary, especially to guide interventional treatment [95–99].
3.3.1.3 Assessment of the severity of the infection
If infection is suspected, it is best to use a tissue culture to identifying pathogens 
[109, 110]. X-rays, computed tomography and magnetic resonance imaging are 
used to evaluate bone infection or abscess formation, as well as to guide surgical 
treatment [86, 96, 97].
3.4 DFU management
3.4.1 Prophylaxis of DFU
Patients at risk of DFU should be managed by an interdisciplinary approach, 
including a diabetologist, a vascular surgeon, a podiatrist, a general surgeon, an 
orthopedic surgeon, a plastic surgeon and other specialists [82, 94, 102]. Stringent 
glycemic control is essential both in primary prevention of DFU and in ensur-
ing wound healing. Management of high blood pressure and dyslipidemia is also 
important [86, 96, 97].
High-risk patients need education about the importance of wearing comfortable 
footwear, rigorous local hygiene, keeping feet dry and avoiding possible causes of local 
trauma (including barefoot walking) and frequent self-examinations [86, 96, 97]. 
Callus debridement, off-loading, and correct treatment of nail pathology are simple but 
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extremely efficient measures for the prevention of foot ulcers [86, 96, 97]. LEADER 
trial suggests that treatment with liraglutide in patients with type 2 diabetes and at high 
risk of CV events did not increase the risk of DFU events and was associated with a 
significantly lower risk of DFU-related amputations compared with placebo [109].
3.4.2 Therapeutic management of DFUs: main principles
Management of DFUs is aimed at correcting the pathogenic triad of neuropathy, 
PAD and infection. Off-loading with appropriate footwear and/or casts, debride-
ment of callus and/or necrotic tissue, revascularization (by-pass grafting or 
intraluminal angioplasty) and infection control are the top priorities [86, 96, 97]. 
These may be aided by special dressings, skin substitutes, growth factors and other 
modalities [111–116]. Special care must be taken to recognize and promptly deal 
with emergencies requiring surgery and other urgent interventions [117].
4. Conclusions
Diabetic retinopathy and diabetic foot ulcer are both disabling complications, 
with a significant impact on the patient's quality of life and healthcare systems 
[118]. Microvascular impairment and local inflammation play a significant role 
in the both pathological mechanisms. Prevention and early detection, along with 
optimal control of blood sugar, hyperlipemia and arterial hypertension are the most 
efficacious measures against these fearful complications.
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